These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

223 related articles for article (PubMed ID: 19004298)

  • 1. The ins and outs of independent IRBs.
    Lis JM; Murray MG
    J Health Life Sci Law; 2008 Oct; 2(1):73, 75-122. PubMed ID: 19004298
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Exception from informed consent: viewpoint of institutional review boards--balancing risks to subjects, community consultation, and future directions.
    Ernst AA; Fish S
    Acad Emerg Med; 2005 Nov; 12(11):1050-5. PubMed ID: 16264073
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A study of warning letters issued to institutional review boards by the United States Food and Drug Administration.
    Bramstedt KA; Kassimatis K
    Clin Invest Med; 2004 Dec; 27(6):316-23. PubMed ID: 15675112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Institutional review board guidance on pediatric research: missed opportunities.
    Wolf LE; Zandecki J; Lo B
    J Pediatr; 2005 Jul; 147(1):84-9. PubMed ID: 16027701
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Enhancing communication among data monitoring committees and institutional review boards.
    Taylor HA; Chaisson L; Sugarman J
    Clin Trials; 2008; 5(3):277-82. PubMed ID: 18559418
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The expanding purview: institutional review boards and the review of human subjects research.
    Borenstein J
    Account Res; 2008; 15(3):188-204. PubMed ID: 18792538
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Public health practice vs research: implications for preparedness and disaster research review by State Health Department IRBs.
    Perlman D
    Disaster Med Public Health Prep; 2008 Oct; 2(3):185-91. PubMed ID: 18845930
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Practice-based research network studies and institutional review boards: two new issues.
    Yawn BP; Graham DG; Bertram SL; Kurland MJ; Dietrich AJ; Wollan PC; Brandt EC; Huff JM; Pace WD
    J Am Board Fam Med; 2009; 22(4):453-60. PubMed ID: 19587261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Protection of human subjects; standards for institutional review boards for clinical investigations--Food and Drug Administration. Final rule.
    Fed Regist; 1981 Jan; 46(17 pt 2):8958-79. PubMed ID: 10249529
    [TBL] [Abstract][Full Text] [Related]  

  • 10. The development and acceptance of a simple tool to aid IRB compliance.
    Vulcano DM
    Qual Manag Health Care; 2012; 21(3):203-8. PubMed ID: 22722526
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medical education research and IRB review: an analysis and comparison of the IRB review process at six institutions.
    Dyrbye LN; Thomas MR; Mechaber AJ; Eacker A; Harper W; Massie FS; Power DV; Shanafelt TD
    Acad Med; 2007 Jul; 82(7):654-60. PubMed ID: 17595560
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The editor and the IRB: should journals notify IRBs about possibly unethical research with human subjects?
    Szidon JP; Swazey JP
    IRB; 1986; 8(5):10-2. PubMed ID: 11653766
    [No Abstract]   [Full Text] [Related]  

  • 13. Clinician educators' experiences with institutional review boards: results of a national survey.
    Dyrbye LN; Thomas MR; Papp KK; Durning SJ
    Acad Med; 2008 Jun; 83(6):590-5. PubMed ID: 18520468
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The purpose, composition, and function of an institutional review board: balancing priorities.
    Enfield KB; Truwit JD
    Respir Care; 2008 Oct; 53(10):1330-6. PubMed ID: 18811996
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nurses on hospital IRBs: a critical voice in protecting human subjects.
    Cassidy VR; Oddi LF
    Nursingconnections; 1993; 6(1):31-8. PubMed ID: 8487874
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Protection of human subjects: categories of research that may be reviewed by the Institutional Review Board (IRB) through an expedited review procedure--FDA. Notice.
    Fed Regist; 1998 Nov; 63(216 Pt 1):60353-6. PubMed ID: 10187395
    [TBL] [Abstract][Full Text] [Related]  

  • 17. FDA overview and current challenges in regulation of human subject protection. Food and Drug Administration.
    Nightingale SL
    J Int Assoc Physicians AIDS Care; 1997 Jan; 3(1):24-6. PubMed ID: 11363959
    [TBL] [Abstract][Full Text] [Related]  

  • 18. The IRB challenge for practice-based research: strategies of the American Academy of Family Physicians National Research Network (AAFP NRN).
    Graham DG; Spano MS; Manning B
    J Am Board Fam Med; 2007; 20(2):181-7. PubMed ID: 17341755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Use of central institutional review boards for multicenter clinical trials in the United States: a review of the literature.
    Check DK; Weinfurt KP; Dombeck CB; Kramer JM; Flynn KE
    Clin Trials; 2013 Aug; 10(4):560-7. PubMed ID: 23666951
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Final regulations amending basic HHS policy for the protection of human research subjects--Department of Health and Human Services. Final rule.
    Fed Regist; 1981 Jan; 46(16 Pt 2):8366-91. PubMed ID: 10249932
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.